As of June 16, 2021, 23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group, completed their previously announced business combination. The transaction, which was approved on June 10, 2021 by VG Acquisition Corp.’s shareholders, uniquely positions 23andMe to revolutionize personalized healthcare and therapeutic development through human genetics. The combined company is called 23andMe Holding Co. and will be traded on The Nasdaq Global Select Market (“Nasdaq”) beginning on June 17, 2021 under the new ticker symbol “ME”

Virgin Group Acquisition Corp. II (VGAC II) is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We are primarily focused on effecting a business combination with consumer-facing businesses in the U.S. and Western Europe, with a focus on businesses that provide consumer experiences in the sectors in which Virgin has historically created significant shareholder value, including travel & leisure, financial services, health & wellness, technology & internet-enabled, music & entertainment, media & mobile and renewable energy / resource efficiency.